Publicaciones en colaboración con investigadores/as de KU Leuven (20)

2023

  1. Correction to: Improving clinical paediatric research and learning from COVID-19: recommendations by the Conect4Children expert advice group (Pediatric Research, (2022), 91, 5, (1069-1077), 10.1038/s41390-021-01587-3)

    Pediatric Research

  2. Long-Term Treatment and Effect of Discontinuation of Calcifediol in Postmenopausal Women with Vitamin D Deficiency: A Randomized Trial

    Journal of Bone and Mineral Research, Vol. 38, Núm. 4, pp. 471-479

2022

  1. An HNRNPK-specific DNA methylation signature makes sense of missense variants and expands the phenotypic spectrum of Au-Kline syndrome

    American Journal of Human Genetics, Vol. 109, Núm. 10, pp. 1867-1884

  2. Improving clinical paediatric research and learning from COVID-19: recommendations by the Conect4Children expert advice group

    Pediatric Research, Vol. 91, Núm. 5, pp. 1069-1077

  3. Reply to Calcifediol Is Not Superior to Cholecalciferol in Improving Vitamin D Status in Postmenopausal Women

    Journal of Bone and Mineral Research

  4. Romosozumab efficacy and safety in European patients enrolled in the FRAME trial

    Osteoporosis International, Vol. 33, Núm. 12, pp. 2527-2536

2021

  1. Calcifediol is superior to cholecalciferol in improving vitamin D status in postmenopausal women: a randomized trial

    Journal of Bone and Mineral Research, Vol. 36, Núm. 10, pp. 1967-1978

2016

  1. Analysis of plasminogen genetic variants in multiple sclerosis patients

    G3: Genes, Genomes, Genetics, Vol. 6, Núm. 7, pp. 2073-2079

  2. Clinical delineation of the PACS1-related syndrome-Report on 19 patients

    American Journal of Medical Genetics, Part A, Vol. 170, Núm. 3, pp. 670-675

2015

  1. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes

    New England Journal of Medicine, Vol. 373, Núm. 3, pp. 232-242

2013

  1. The use of imaging for electrophysiological and devices procedures: A report from the first European Heart Rhythm Association Policy Conference, jointly organized with the European Association of Cardiovascular Imaging (EACVI), the Council of Cardiovascular Imaging and the European Society of Cardiac Radiology

    Europace, Vol. 15, Núm. 7, pp. 927-936

  2. Treatment of idiopathic pulmonary fibrosis with Ambrisentan: A parallel, randomized trial

    Annals of Internal Medicine, Vol. 158, Núm. 9, pp. 641-649

2011

  1. Consensus document regarding cardiovascular safety at sports arenas

    European Heart Journal, Vol. 32, Núm. 17, pp. 2119-2124

  2. Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide

    Osteoporosis International

2009

  1. Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled european study of forsteo (EUROFORS)

    Journal of Bone and Mineral Research, Vol. 24, Núm. 4, pp. 726-736

2008

  1. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis

    Journal of Clinical Endocrinology and Metabolism, Vol. 93, Núm. 3, pp. 852-860

  2. Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment

    Journal of Bone and Mineral Research, Vol. 23, Núm. 10, pp. 1591-1600

2007

  1. Teriparatide or alendronate in glucocorticoid-induced osteoporosis

    New England Journal of Medicine, Vol. 357, Núm. 20, pp. 2028-2039

2006

  1. Reply by Boonen et al. [17]

    Journal of the American Geriatrics Society

  2. Safety and efficacy of teriparatide in elderly women with established osteoporosis: Bone anabolic therapy from a geriatric perspective

    Journal of the American Geriatrics Society, Vol. 54, Núm. 5, pp. 782-789